📰 Beigene News
Page 11 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
April 29, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) – Analysts at SVB Leerink issued their FY2027 earnings per share (EPS) estimates for BeiGene in a research report issued to clients and investors on Tuesday, April 25th. SVB Leerink analyst A. Berens forecasts that the company will post earnings per share of $5.40 for the year. SVB Leerink […]
April 26, 2023
BEIGENE, LTD. : News, information and stories for BEIGENE, LTD. | Nasdaq: BGNE | Nasdaq
April 25, 2023
Financial Information On April 25, 2023, BeiGene, Ltd. filed the 2022 Annual Report with the Science and Technology Innovation Board of the Shanghai Stock... | April 25, 2023
April 21, 2023
Simplicity Solutions LLC grew its position in BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,527 shares of the company’s stock after purchasing an additional 202 shares during the period. Simplicity Solutions LLC’s holdings in BeiGene were […]
April 21, 2023
The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
April 20, 2023
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting ... | April 20, 2023
April 17, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have […]
April 17, 2023
MapKure, LLC, BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective... | April 17, 2023
April 17, 2023
BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in... | April 17, 2023
April 14, 2023
Chinas pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.